Llwytho...
Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma
Approved by the Food and Drug Administration in 2011, the anti-cytotoxic T-lymphocyte-associated protein 4 checkpoint inhibitor ipilimumab has delivered a survival benefit of ≥3 years in a subset of metastatic melanoma patients. After participating in the registration trial, patients were treated wi...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Oncol Lett |
|---|---|
| Prif Awduron: | , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
D.A. Spandidos
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4734313/ https://ncbi.nlm.nih.gov/pubmed/26893783 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2015.4069 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|